Blackstone BioMed Life Science Real Estate L.P.

Blackstone BioMed Life Science Real Estate L.P. is a long-term, perpetual capital, core+ return fund managed by Blackstone, focusing on life science office investments primarily in the United States. The fund owns BioMed Realty, the largest private provider of real estate solutions to the life science and technology industries, with a portfolio of approximately 17 million square feet of high-quality life science real estate in leading innovation markets across the U.S. and the United Kingdom. BioMed Realty's properties are strategically located in cities such as Boston/Cambridge, San Francisco, San Diego, Seattle, Boulder, and Cambridge, U.K., providing mission-critical infrastructure to support the growth of life science and technology companies.

The fund's investment strategy centers on acquiring and developing properties that cater to the specialized needs of life science tenants, including state-of-the-art laboratories and office spaces. By leveraging Blackstone's global network and financial strength, the fund aims to capitalize on the growing demand for life science real estate, driven by advancements in biotechnology, pharmaceuticals, and medical research. The portfolio includes both stabilized assets and properties under development, ensuring a balanced approach to risk and return.

Since its inception, Blackstone BioMed Life Science Real Estate L.P. has demonstrated a commitment to enhancing the life science ecosystem by providing high-quality spaces that foster innovation and collaboration. The fund's focus on core+ return strategies reflects a dedication to delivering attractive, risk-adjusted returns to its investors while supporting the expansion of critical infrastructure for the life science sector.